Get started

Financials · CTKB

Cytek Biosciences Inc. (CTKB) financials

For the twelve months ended Sep 30, 2026, Cytek Biosciences Inc. reported $207.65M of revenue and -$81.20M of net income.

Revenue, TTM
$207.65M
Revenue growth, YoY
+5.5%
Net income, TTM
-$81.20M
Net margin
-39.1%
Free cash flow, TTM
-$13.48M
EPS, diluted, TTM
-$0.64
Cash
$66.81M
P/S
3.71
Market cap
$770.3M
Annual revenue$201.49M
FY2020FY2025
Annual net income-$66.54M
FY2020FY2025
Annual free cash flow-$8.77M
FY2020FY2025

CTKB revenue and earnings growth

CTKB revenueQ3 2026$53.23M

Quarter YoY
+1.8%
QoQ
+10.6%
FY YoY
+0.5%
5Y CAGR
+16.8%

CTKB revenue was $53.23M in fiscal Q3 2026 (ended Sep 30, 2026), up 1.8% from a year earlier and up 10.6% from the prior quarter. For the full fiscal 2025 it was $201.49M, up 0.5% from fiscal 2024. Compound annual growth was +16.8% over 5 years. It rose in each of the last 5 fiscal years. Fiscal 2025 is the highest of the 6 fiscal years on file.

CTKB net incomeQ3 2026-$6.10M

CTKB net income was -$6.10M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$5.48M a year earlier. For the full fiscal 2025 it was -$66.54M, compared with -$6.02M in fiscal 2024.

CTKB EPSQ3 2026-$0.05

CTKB diluted EPS was -$0.05 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.04 a year earlier. For the full fiscal 2025 it was -$0.52, compared with -$0.05 in fiscal 2024.

CTKB free cash flowQ3 2026-$5.96M

CTKB free cash flow was -$5.96M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$4.55M a year earlier. For the full fiscal 2025 it was -$8.77M, compared with $21.85M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$201.49M$200.45M$193.01M$164.04M$127.95M$92.84M
Cost of revenue$97.03M$89.35M$83.59M$63.06M$48.81M$41.13M
Gross profit$104.46M$111.11M$109.43M$100.97M$79.14M$51.71M
Research and development$36.47M$39.40M$44.15M$34.86M$24.44M$13.69M
Selling, general and admin$58.94M$43.11M$43.97M$34.69M$20.84M$9.37M
Operating income-$40.38M-$20.52M-$27.84M-$1.80M$9.16M$13.66M
Interest expense$474.0K-$5.24M$2.07M$2.57M$1.74M$333.0K
Pre-tax income-$29.84M-$5.70M-$15.71M$1.26M$5.94M$14.43M
Income tax$36.70M$320.0K-$3.56M-$1.22M$2.91M-$4.98M
Net income-$66.54M-$6.02M-$12.15M$2.48M$3.03M$19.41M
EPS, basic-$0.52-$0.05-$0.09$0.02$0.00$0.11
EPS, diluted-$0.52-$0.05-$0.09$0.02$0.00$0.10
Diluted shares127.7M130.6M135.3M138.6M81.5M32.6M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$90.85M$98.75M$167.63M$299.50M$364.62M$166.12M
Receivables$62.51M$60.59M$55.93M$48.86M$29.76M$16.99M
Inventory$48.43M$43.89M$60.88M$48.15M$32.17M$23.02M
Current assets$392.00M$396.45M$392.06M$454.02M$431.73M$208.62M
Goodwill$16.70M$16.66M$16.18M$10.14M$10.14M$476.0K
Total assets$461.54M$499.50M$494.46M$519.48M$463.31M$219.98M
Current liabilities$77.80M$67.66M$56.23M$49.04M$33.18M$26.54M
Total liabilities$119.80M$103.76M$101.39M$93.93M$57.92M$41.69M
Shareholders' equity$341.74M$395.74M$393.06M$425.55M$405.38M-$16.03M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$4.69M$25.38M$5.28M-$12.23M$4.63M$15.16M
Capital expenditures$4.08M$3.52M$4.65M$9.75M$4.36M$1.55M
Free cash flow-$8.77M$21.85M$633.0K-$21.98M$266.0K$13.61M
Investing cash flow$10.12M-$82.97M-$93.89M-$55.91M-$20.99M-$1.55M
Financing cash flow-$13.43M-$15.82M-$41.81M$5.51M$213.56M$122.61M
Share repurchases$15.07M$21.61M$44.15M$0$0-
Stock-based compensation$24.59M$26.85M$22.05M$16.59M$6.59M$611.0K
Depreciation and amortization$7.58M$7.21M$6.05M$2.49M$1.24M$603.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY0.5%3.9%17.7%28.2%37.8%-
Net income growth, YoY----17.9%-84.4%-
Gross margin51.8%55.4%56.7%61.6%61.9%55.7%
Operating margin-20.0%-10.2%-14.4%-1.1%7.2%14.7%
Net margin-33.0%-3.0%-6.3%1.5%2.4%20.9%
Free cash flow margin-4.4%10.9%0.3%-13.4%0.2%14.7%
Return on equity-19.5%-1.5%-3.1%0.6%0.7%-
Return on assets-14.4%-1.2%-2.5%0.5%0.7%8.8%
Current ratio5.045.866.979.2613.017.86

Source: XBRL data Cytek Biosciences Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CTKB peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CTKB$207.65M+5.5%-$81.20M-39.1%$770.3M
A$7.37B+8.6%$1.44B19.5%$50.80B
WAT$4.64B+52.5%$166.14M3.6%$46.83B
MTD$4.20B+6.5%$934.07M22.2%$35.31B
RVTY$2.91B+4.1%$237.55M8.2%$17.93B
AVTR$6.64B+0.9%$337.20M5.1%$10.78B
BIO$2.59B+1.4%$1.02B39.5%$10.44B
BRKR$3.51B+2.2%-$123.40M-3.5%$10.16B
TXG$618.58M-3.6%-$67.08M-10.8%$8.48B

CTKB FAQ

9 questions
  • What is CTKB revenue?
    Cytek Biosciences Inc. (CTKB) reported $207.65M of revenue for the twelve months ended Sep 30, 2026. That is up 5.5% from the year before. Revenue for fiscal 2025 was $201.49M.
  • Is CTKB profitable?
    No. Cytek Biosciences Inc. reported a net loss of $81.20M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CTKB have?
    Cytek Biosciences Inc. reported $66.81M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CTKB revenue growing?
    Cytek Biosciences Inc.'s revenue changed +0.5% in fiscal 2025, to $201.49M. Its compound annual growth rate was +16.8% over 5 years.
  • What is CTKB gross margin?
    Cytek Biosciences Inc.'s gross profit was $113.69M on $207.65M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 54.7%.
  • What is CTKB free cash flow?
    Cytek Biosciences Inc. generated -$13.48M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$6.59M less capital expenditures.
  • What is CTKB earnings per share?
    Diluted earnings per share were -$0.64 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CTKB last report financial results?
    The latest statements here come from Cytek Biosciences Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this CTKB financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cytek Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.